It Looks Like We've Made a Big Step in Combating Alzheimer's
Townhall
Last updated: September 8, 2026
The U.S. Food and Drug Administration (FDA) has approved Leqembi, an injection designed to combat Alzheimer's disease by targeting amyloid plaques in the brain. This approval represents a significant advancement in the fight against the neurodegenerative condition.
- Key Developments: Leqembi, developed by Eisai and Biogen, is an antibody that targets and removes amyloid-beta plaques, a hallmark of Alzheimer's disease. Clinical trials demonstrated that Leqembi can modestly slow cognitive decline in patients with early-stage Alzheimer's. The drug aims to improve the quality of life for patients and restore memory functions.
- Impact and Implications: The FDA's accelerated approval pathway allowed for Leqembi's conditional endorsement based on its ability to reduce amyloid plaques, with a confirmatory trial still pending. This marks the second drug in recent years targeting amyloid plaques, signaling a new era in Alzheimer's treatment. While Leqembi offers a promising new therapeutic option, its effectiveness and long-term impact will continue to be monitored. The drug's administration requires regular infusions, and potential side effects, including brain swelling and bleeding, need careful management by healthcare providers.
